시장보고서

상품코드

1797670

세계의 여성 건강 POC 검사 시장 : 제품 유형, 연령, 샘플 유형, 검사 유형, 기술, 용도, 유통경로, 최종사용자, 지역별(-2032년)

Global Point-of-Care Testing for Women Health Market Research by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, by End User, and by Region Forecast till 2032

발행일: 2025년 07월 | 리서치사:

Market Research Future | 페이지 정보: 영문 350 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 여성 건강 POC 검사 시장 규모는 2024년부터 2032년까지 연평균 6.26%의 견조한 성장세를 보이며 2032년에는 287억 7,000만 달러 규모로 성장할 것으로 예측됩니다.

여성 건강 POC 검사는 생식 건강, 감염, 임신 관련 합병증과 같은 심각한 질환에 대한 즉각적이고 휴대 가능한 결과를 제공하는 다목적의 간편한 진단 도구입니다. 처음에는 장애인을 위해 개발되었지만, 현재는 병원, 클리닉, 가정에서도 사용할 수 있습니다. 신속성과 더불어 저렴한 가격과 높은 신뢰성으로 인해 전체 예방 의료 및 중증화 이전의 조기 의료 개입에서 중요한 역할을 담당하고 있습니다.

성병, 요로감염증, HPV 등 여성에게 흔한 질환이 증가하고 있는 것은 신속한 검사 도구의 필요성을 강조하고 있습니다. POC 검사는 신속하고 신뢰할 수 있는 결과를 제공함으로써 이러한 과제에 대응하고 조기 진단 및 개입을 지원합니다. 여성의 건강은 적시 치료와 접근 가능한 검사 솔루션에 크게 의존하고 있으며, 감염성 질환에 대한 부담이 증가함에 따라 채택을 촉진하고 있습니다.

지역별 분석

북미 시장은 신속하고 신뢰할 수 있는 검사에 대한 소비자 수요를 배경으로 확대되고 있습니다. 높은 인지도와 잘 정비된 의료시스템에 힘입어 병원뿐만 아니라 재택의료 환경에서도 폭넓게 활용되고 있습니다. 2023년 북미 시장에서는 미국이 57억 3,544만 달러, 캐나다가 8억 8,972만 달러, 멕시코가 4억 2,632만 달러 시장 규모를 기록할 것으로 예측됩니다.

유럽 시장에서는 혁신이 활발하게 일어나고 있으며, 개인 맞춤형 의료에 대한 관심이 높아지고 있습니다. 생식 건강에서 만성 질환에 이르기까지 질병의 조기 발견을 주요 목적으로 하는 최첨단 진단 플랫폼의 활용이 확대되고 있습니다. 2023년에는 독일이 12억 2,006만 달러, 영국이 9억 6,019만 달러, 프랑스가 7억 7,511만 달러로 유럽 상위 3위를 차지했습니다.

아시아태평양은 중국, 인도, 동남아시아의 의료 접근성 확대에 힘입어 괄목할 만한 성장 잠재력을 보이고 있습니다. 2023년에는 중국(7억 5,165만 달러), 인도(6억 3,481만 달러), 일본(6억 731만 달러)이 주요 시장을 형성했습니다. 임신 관련 합병증과 만성질환 증가로 POCT 솔루션에 대한 의존도가 높아지고 있습니다.

세계의 여성 건강 관련 POC 검사(POC Test) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이와 예측, 각종 부문별/지역별/주요 국가별 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

SWISS PRECISION DIAGNOSTICS GMBH-CLEARBLUE
WONDFO
CHURCH & DWIGHT CO., INC.-FIRST RESPONSE
HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.
W.H.P.M., INC.
SEKISUI DIAGNOSTICS
INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD
YANGZHOU VIOMED
COFOE MEDICAL TECHNOLOGY CO., LTD.
CHUNGDO PHARM CO., LTD.
ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.
EASY HEALTHCARE CORPORATION

제17장 데이터 인용

LSH 25.09.02

Global Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Mullerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, B-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032

Industry Overview

The Global Point-of-Care Testing for Women's Health Market is forecasted to expand to USD 28.77 billion by 2032, reflecting a steady 6.26% CAGR during 2024-2032. POCT for women's health is a multipurpose, easy-to-access diagnostic tool giving immediate and on-the-go results of critical conditions, such as reproductive health, infectious diseases, and pregnancy-related complications. Originally intended for the disabled, these tests are also accessible at hospitals, clinics, or simply at home. Their rapidity, and at the same time, good affordability and reliability allow them to become keys in the whole preventive care and early medical intervention process serious cases.

Growing cases of sexually transmitted infections, urinary tract infections, and HPV among women highlight the urgent need for rapid detection tools. POC testing addresses this gap with quick and reliable results, supporting early diagnosis and intervention. The rising infection burden is propelling adoption, as women's health outcomes depend on timely treatment and accessible testing solutions.

Key Company Development

Swiss Precision Diagnostics GmbH has demonstrated consistent innovation in advancing diagnostic solutions for women's health. In August 2023, the company launched the Clearblue Menopause Stage Indicator, a first-of-its-kind home-use product that evaluates menopause stages by integrating urinary FSH measurements with age and cycle data. This innovation empowers women with greater understanding of reproductive transitions, fostering informed health decisions. Complementing this milestone, SPD in August 2020 implemented the Matrix Gemini LIMS to optimize data management in pregnancy studies. This technology enhanced accessibility, streamlined laboratory workflows, and improved biobank operations, reflecting the company's strong emphasis on digital transformation. These strategic moves reinforce SPD's leadership in combining product innovation and advanced technologies to deliver precision-driven women's health diagnostics.

Key Players

Major players in the global point-of-care testing for women health market are Swiss Precision Diagnostics GmbH (SPD), Wondfo, Church & Dwight Co., Inc., Hangzhou Singclean, Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, Innovita Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., and Chungdo Pharm Co., Ltd.

Report Attribute Details

Market Size 2023 USD 16,627.22 Million

Market Size 2032 USD 28,768.16 Million

CAGR (2024-2032) 6.26%

Base Year 2023

Market Forecast Period 2024-2032

Historical Data 2019-2024

Industry Segmentations CAGR (2024-2032)

By Product: Instruments/ Devices - 7.72%, Reagents & Kits - 5.97%.

By Age: Adolescent - 8.18%, Adult - 6.20%.

By Sample Type: Serum - 5.27%, Plasma - 4.30%.

By Test Type: Testosterone Test - 4.12%, Estradiol Test - 3.53%.

By Technology: Colloidal Gold Lateral Flow Assays - 7.19%, Fluorescence Immunoassays - 5.46%.

By Application: Gestational Diabetes - 5.34%, Vaginal Infection - 4.08%.

By Distribution Channel: Offline - 5.49%, Online - 7.35%.

By End User: Hospitals - 5.42 %, Diagnostic Laboratories - 6.96%.

Regional Analysis

The women's health POCT market in North America rides on the back of consumer demand for quick and reliable testing. High awareness in conjunction with well-organized healthcare systems acts as a springboard for wide use in hospital as well as home-care environments. In 2023, North America's market was led by the US, followed by Canada and Mexico, with respective market values of USD 5,735.44 million, USD 889.72 million, and USD 426.32 million.

Innovation is thriving in the European market, and there is an increasing emphasis on personalized medicine. The use of cutting-edge diagnostic platforms is growing, with the primary objective being early detection of diseases that range from reproductive health to chronic conditions. In 2023, Germany, the UK, and France were the top three European markets, contributing USD 1,220.06 million, USD 906.19 million, and USD 775.11 million.

Asia-Pacific demonstrates remarkable growth potential, propelled by expanding healthcare access in China, India, and Southeast Asia. In 2023, the APAC region China, India, and Japan, is the leading market, with market sizes of USD 751.65 million, USD 634.81 million, and USD 607.31 million. A rising incidence of pregnancy-related complications and chronic illnesses is driving reliance on POCT solutions.

Markets in the Middle East, Africa, and South America are witnessing steady adoption of POCT, largely due to limited access to traditional laboratory infrastructure. Portable diagnostic technologies are emerging as vital tools in addressing reproductive health challenges.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES IN WOMEN
- 4.2.2 INCREASING CASES OF INFERTILITY AMONG WOMEN
- 4.2.3 GROWING STRATEGIC INITIATIVES ASSOCIATED WITH THE POINT-OF-CARE TESTING FOR WOMEN HEALTH
4.3 RESTRAINTS
- 4.3.1 INACCURACY OF POINT OF CARE DIAGNOSTIC TESTS
4.4 OPPORTUNITY
- 4.4.1 RISING AWARENESS AND HEALTH INITIATIVES
- 4.4.2 HIGH COST OF DIAGNOSTIC IMAGING SYSTEMS AND PROCEDURES

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET
5.3 CONSUMER PREFERENCE ANALYSIS
5.4 REGULATORY LANDSCAPE AND ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS
- 5.4.1 REGULATORY LANDSCAPE
- 5.4.2 ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS
5.5 EFFECTS OF TRANSITION OF IVDD TO IVDR ON GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET

6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 INSTRUMENTS/DEVICES
6.3 REAGENTS & KITS
6.4 CONSUMABLES

7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE

7.1 OVERVIEW
7.2 ADOLESCENT
7.3 ADULT
7.4 GERIATRIC

8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE

8.1 OVERVIEW
8.2 SERUM
8.3 PLASMA
8.4 WHOLE BLOOD
8.5 URINE
8.6 OTHERS

9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE

9.1 OVERVIEW
9.2 TESTOSTERONE TEST
9.3 ESTRADIOL TEST
9.4 ANTI-MULLERIAN HORMONE TEST
9.5 PROLACTIN TEST
9.6 PROGESTERONE TEST
9.7 FOLLICLE-STIMULATING HORMONE TEST
9.8 LUTEINIZING HORMONE TEST
9.9 B-HCG TEST
9.10 OTHERS

10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY

10.1 OVERVIEW
10.2 COLLOIDAL GOLD LATERAL FLOW ASSAYS
10.3 FLUORESCENCE IMMUNOASSAYS
10.4 LAB-ON-A-CHIP
10.5 OTHERS

11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION

11.1 OVERVIEW
11.2 GESTATIONAL DIABETES
11.3 VAGINAL INFECTION
11.4 URINARY TRACT INFECTION
11.5 CERVICAL CANCER OR PRE-CANCEROUS CONDITIONS
11.6 HEMOGLOBIN DEFICIENCY
11.7 BREAST CANCER
11.8 THYROID DISEASE
11.9 SEXUALLY TRANSMITTED INFECTIONS
- 11.9.1 CHLAMYDIA
- 11.9.2 GONORRHEA
- 11.9.3 HIV
- 11.9.4 SYPHILIS
- 11.9.5 OTHERS
11.10 FERTILITY CONDITIONS
- 11.10.1 POLYCYSTIC OVARY SYNDROME
- 11.10.2 OVULATION DISORDERS
- 11.10.3 OTHERS
11.11 PREGNANCY TESTING
11.12 OTHERS

12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW
12.2 OFFLINE
- 12.2.1 HOSPITAL PHARMACIES
- 12.2.2 RETAIL PHARMACIES
- 12.2.3 HYPERMARKET/SUPERMARKET
12.3 ONLINE
- 12.3.1 E-COMMERCE PLATFORMS
- 12.3.2 ONLINE PHARMACIES

13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER

13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC LABORATORIES
13.4 HOME SETTINGS
13.5 OTHERS

14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION

14.1 OVERVIEW
14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.2 CANADA
- 14.2.3 MEXICO
14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.2 FRANCE
- 14.3.3 UK
- 14.3.4 ITALY
- 14.3.5 SPAIN
- 14.3.6 REST OF EUROPE
14.4 ASIA-PACIFIC
- 14.4.1 CHINA
- 14.4.2 INDIA
- 14.4.3 JAPAN
- 14.4.4 AUSTRALIA
- 14.4.5 SOUTH KOREA
- 14.4.6 SOUTH EAST ASIA
  - 14.4.6.1 MALAYSIA
  - 14.4.6.2 SINGAPORE
  - 14.4.6.3 THAILAND
  - 14.4.6.4 VIETNAM
  - 14.4.6.5 PHILIPPINES
  - 14.4.6.6 INDONESIA
  - 14.4.6.7 REST OF SOUTH EAST ASIA
- 14.4.7 REST OF ASIA-PACIFIC
14.5 REST OF THE WORLD
- 14.5.1 MIDDLE EAST & AFRICA
- 14.5.2 SOUTH AMERICA
  - 14.5.2.1 BRAZIL
  - 14.5.2.2 ARGENTINA
  - 14.5.2.3 CHILE
  - 14.5.2.4 REST OF SOUTH AMERICA

15 COMPETITIVE LANDSCAPE

15.1 INTRODUCTION
15.2 MARKET SHARE ANALYSIS, 2023
15.3 COMPETITOR DASHBOARD
15.4 PUBLIC PLAYERS STOCK SUMMARY
15.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
15.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 15.6.1 PRODUCT LAUNCH
- 15.6.2 TECHNOLOGY LAUNCH
- 15.6.3 AQUISITION
- 15.6.4 PRODUCT RECOGNITION

16 COMPANY PROFILES

16.1 SWISS PRECISION DIAGNOSTICS GMBH - CLEARBLUE
- 16.1.1 COMPANY OVERVIEW
- 16.1.2 PRODUCTION OVERVIEW
- 16.1.3 FINANCIAL OVERVIEW
- 16.1.4 PRODUCTS OFFERED
- 16.1.5 DISTRIBUTION CHANNEL
- 16.1.6 PRICE ANALYSIS
- 16.1.7 PROMOTION STRATEGY
- 16.1.8 TECHNOLOGY ANALYSIS
- 16.1.9 KEY DEVELOPMENTS
- 16.1.10 SWOT ANALYSIS
- 16.1.11 KEY STRATEGIES
16.2 WONDFO
- 16.2.1 COMPANY OVERVIEW
- 16.2.2 PRODUCTION OVERVIEW
- 16.2.3 FINANCIAL OVERVIEW
- 16.2.4 PRODUCTS OFFERED
- 16.2.5 TECHNOLOGY
- 16.2.6 KEY DEVELOPMENTS
- 16.2.7 SWOT ANALYSIS
- 16.2.8 KEY STRATEGIES
16.3 CHURCH & DWIGHT CO., INC. - FIRST RESPONSE
- 16.3.1 COMPANY OVERVIEW
- 16.3.2 PRODUCTION OVERVIEW
- 16.3.3 FINANCIAL OVERVIEW
- 16.3.4 PRODUCTS OFFERED
- 16.3.5 DISTRIBUTION CHANNEL
- 16.3.6 PRICE ANALYSIS
- 16.3.7 PROMOTION
- 16.3.8 TECHNOLOGY ANALYSIS
- 16.3.9 KEY DEVELOPMENTS
- 16.3.10 SWOT ANALYSIS
- 16.3.11 KEY STRATEGIES
16.4 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.
- 16.4.1 COMPANY OVERVIEW
- 16.4.2 PRODUCTION OVERVIEW
- 16.4.3 FINANCIAL OVERVIEW
- 16.4.4 PRODUCT OFFERED
- 16.4.5 TECHNOLOGY ANALYSIS
- 16.4.6 KEY DEVELOPMENTS
- 16.4.7 KEY STRATEGIES
16.5 W.H.P.M., INC.
- 16.5.1 COMPANY OVERVIEW
- 16.5.2 PRODCUTION OVERVIEW
- 16.5.3 FINANCIAL OVERVIEW
- 16.5.4 PRODUCTS OFFERED
- 16.5.5 TECHNOLOGY ANALYSIS
- 16.5.6 KEY DEVELOPMENTS
- 16.5.7 KEY STRATEGIES
16.6 SEKISUI DIAGNOSTICS
- 16.6.1 COMPANY OVERVIEW
- 16.6.2 PRODUCTION OVERVIEW
- 16.6.3 FINANCIAL OVERVIEW
- 16.6.4 PRODUCTS OFFERED
- 16.6.5 TECHNOLOGY ANALYSIS
- 16.6.6 KEY DEVELOPMENTS
- 16.6.7 SWOT ANALYSIS
- 16.6.8 KEY STRATEGIES
16.7 INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD
- 16.7.1 COMPANY OVERVIEW
- 16.7.2 FINANCIAL OVERVIEW
- 16.7.3 PRODUCTS OFFERED
- 16.7.4 TECHNOLOGY ANALYSIS
- 16.7.5 KEY DEVELOPMENTS
- 16.7.6 KEY STRATEGIES
16.8 YANGZHOU VIOMED
- 16.8.1 COMPANY OVERVIEW
- 16.8.2 PRODUCTION OVERVIEW
- 16.8.3 FINANCIAL OVERVIEW
- 16.8.4 PRODUCTS OFFERED
- 16.8.5 TECHNOLOGY ANALYSIS
- 16.8.6 KEY DEVELOPMENTS
- 16.8.7 KEY STRATEGIES
16.9 COFOE MEDICAL TECHNOLOGY CO., LTD.
- 16.9.1 COMPANY OVERVIEW
- 16.9.2 PRODUCTION OVERVIEW
- 16.9.3 FINANCIAL OVERVIEW
- 16.9.4 PRODUCTS OFFERED
- 16.9.5 KEY DEVELOPMENTS
- 16.9.6 TECHNOLOGY ANALYSIS
- 16.9.7 SWOT ANALYSIS
- 16.9.8 KEY STRATEGIES
16.10 CHUNGDO PHARM CO., LTD.
- 16.10.1 COMPANY OVERVIEW
- 16.10.2 PRODUCTION OVERVIEW
- 16.10.3 FINANCIAL OVERVIEW
- 16.10.4 PROUDCTS OFFERED
- 16.10.5 TECHNOLOGY ANALYSIS
- 16.10.6 KEY DEVELOPMENTS
- 16.10.7 KEY STRATEGIES
16.11 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.
- 16.11.1 COMPANY OVERVIEW
- 16.11.2 PRODUCTION OVERVIEW
- 16.11.3 FINANCIAL OVERVIEW
- 16.11.4 PRODUCTS OFFERED
- 16.11.5 TECHNOLOGY ANALYSIS
- 16.11.6 KEY DEVELOPMENTS
- 16.11.7 SWOT ANALYSIS
- 16.11.8 KEY STRATEGIES
16.12 EASY HEALTHCARE CORPORATION
- 16.12.1 COMPANY OVERVIEW
- 16.12.2 PRODUCTION OVERVIEW
- 16.12.3 FINANCIAL OVERVIEW
- 16.12.4 PRODUCTS OFFERED
- 16.12.5 TECHNOLOGY
- 16.12.6 KEY DEVELOPMENTS
- 16.12.7 KEY STRATEGIES

세계의 여성 건강 POC 검사 시장 : 제품 유형, 연령, 샘플 유형, 검사 유형, 기술, 용도, 유통경로, 최종사용자, 지역별(-2032년)

Global Point-of-Care Testing for Women Health Market Research by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, by End User, and by Region Forecast till 2032

지역별 분석

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

제5장 시장 요인 분석

제6장 세계의 여성 건강 POC 검사 시장 : 제품별

제7장 세계의 여성 건강 POC 검사 시장 : 연령별

제8장 세계의 여성 건강 POC 검사 시장 : 샘플 유형별

제9장 세계의 여성 건강 POC 검사 시장 : 검사 유형별

제10장 세계의 여성 건강 POC 검사 시장 : 기술별

제11장 세계의 여성 건강 POC 검사 시장 : 용도별

제12장 세계의 여성 건강 POC 검사 시장 : 유통 채널별

제13장 세계의 여성 건강 POC 검사 시장 : 최종사용자별

제14장 세계의 여성 건강 POC 검사 시장 : 지역별

제15장 경쟁 구도

제16장 기업 개요